Miri Zektser

526 total citations
15 papers, 297 citations indexed

About

Miri Zektser is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Miri Zektser has authored 15 papers receiving a total of 297 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Genetics, 6 papers in Hematology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Miri Zektser's work include Diabetes and associated disorders (4 papers), Multiple Myeloma Research and Treatments (4 papers) and Lymphoma Diagnosis and Treatment (4 papers). Miri Zektser is often cited by papers focused on Diabetes and associated disorders (4 papers), Multiple Myeloma Research and Treatments (4 papers) and Lymphoma Diagnosis and Treatment (4 papers). Miri Zektser collaborates with scholars based in Israel, United States and Greece. Miri Zektser's co-authors include Alan Jotkowitz, Leonid Barski, Lior Zeller, Elena Shleyfer, Yaniv Almog, Roman Nevzorov, Ilana Harman‐Boehm, Arie Apel, Maya Koren‐Michowitz and Ofir Wolach and has published in prestigious journals such as Blood, Cancer and International Journal of Molecular Sciences.

In The Last Decade

Miri Zektser

15 papers receiving 293 citations

Peers

Miri Zektser
Miri Zektser
Citations per year, relative to Miri Zektser Miri Zektser (= 1×) peers Andrea Luczay

Countries citing papers authored by Miri Zektser

Since Specialization
Citations

This map shows the geographic impact of Miri Zektser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miri Zektser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miri Zektser more than expected).

Fields of papers citing papers by Miri Zektser

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miri Zektser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miri Zektser. The network helps show where Miri Zektser may publish in the future.

Co-authorship network of co-authors of Miri Zektser

This figure shows the co-authorship network connecting the top 25 collaborators of Miri Zektser. A scholar is included among the top collaborators of Miri Zektser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miri Zektser. Miri Zektser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
2.
Bairey, Osnat, Alexandra Amiel, Shlomit Yust‐Katz, et al.. (2023). A phase 2 study of ibrutinib maintenance following first‐line high‐dose methotrexate‐based chemotherapy for elderly patients with primary central nervous system lymphoma. Cancer. 129(24). 3905–3914. 13 indexed citations
3.
Zektser, Miri, et al.. (2022). Primary Central Nervous System Lymphoma: Clinical Characteristics, Treatment Options and Therapeutic Outcome in 36 Patients. A Single Center Experience.. PubMed. 24(10). 654–660. 2 indexed citations
4.
Iraqi, Muhammed, Avishay Edri, Yariv Greenshpan, et al.. (2022). Blocking the PCNA/NKp44 Checkpoint to Stimulate NK Cell Responses to Multiple Myeloma. International Journal of Molecular Sciences. 23(9). 4717–4717. 10 indexed citations
5.
Apel, Arie, Yishai Ofran, Alexander Gural, et al.. (2021). Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice. American Journal of Hematology. 96(7). 790–795. 21 indexed citations
6.
Barki‐Harrington, Liza, Orna Baron‐Epel, Adir Shaulov, et al.. (2021). Willingness and concerns of transfusion-dependent hematological patients toward the option of home transfusion therapy. Palliative Medicine. 35(5). 927–932. 6 indexed citations
8.
Gatt, Moshe E., Adir Shaulov, Eirini Katodritou, et al.. (2020). Characteristics and outcome of multiple myeloma patients presenting with anaemia only: A retrospective multi-centre study. Leukemia Research. 101. 106498–106498. 2 indexed citations
9.
Ganzel, Chezi, Ron Ram, Alexander Gural, et al.. (2020). Venetoclax is safe and efficacious in relapsed/refractory AML. Leukemia & lymphoma. 61(9). 2221–2225. 30 indexed citations
10.
Gatt, Moshe E., Iuliana Vaxman, Tamar Tadmor, et al.. (2020). Daratumumab for relapsed AL amyloidosis—When cumulative real‐world data precedes clinical trials: A multisite study and systematic literature review. European Journal Of Haematology. 106(2). 184–195. 18 indexed citations
11.
Apel, Arie, Yishai Ofran, Ofir Wolach, et al.. (2020). Safety and efficacy of blinatumomab: a real world data. Annals of Hematology. 99(4). 835–838. 21 indexed citations
12.
Barski, Leonid, et al.. (2013). New approaches to the use of insulin in patients with diabetic ketoacidosis. European Journal of Internal Medicine. 24(3). 213–216. 17 indexed citations
13.
Barski, Leonid, Roman Nevzorov, Alan Jotkowitz, et al.. (2013). Comparison of Diabetic Ketoacidosis in Patients With Type-1 and Type-2 Diabetes Mellitus. The American Journal of the Medical Sciences. 345(4). 326–330. 70 indexed citations
14.
Barski, Leonid, Roman Nevzorov, Alan Jotkowitz, et al.. (2012). Diabetic ketoacidosis: clinical characteristics, precipitating factors and outcomes of care.. PubMed. 14(5). 299–303. 59 indexed citations
15.
Barski, Leonid, Ilana Harman‐Boehm, Roman Nevzorov, et al.. (2011). Gender-Related Differences in Clinical Characteristics and Outcomes in Patients with Diabetic Ketoacidosis. Gender Medicine. 8(6). 372–377. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026